سعر متريكازون 50/25مكجم 120 جرعة بخاخ 2026

Fluticasone propionate 50 mcg + salmeterol 25 mcg per metered actuation, pressurised inhalation (Metricason, MDI Pharma); one inhaler with 120 metered actuations.

• Regular treatment of asthma where a combination of LABA and inhaled corticosteroid is appropriate (not controlled on ICS plus as-needed SABA, or already controlled on ICS plus LABA).Population: Adults and adolescents >=12 years; children >=4 years for 25/50 onlyelectronic medicines compendium (eMC)
• Treatment of asthma in patients 12 years and older not adequately controlled on a long-term controller or warranting ICS plus LABA; not for relief of acute bronchospasm.Population: Adults and adolescents >=12 yearsDailyMed (U.S. NLM)

• Very common: headache, nasopharyngitis. Common: oral/throat candidiasis, pneumonia, hoarseness/dysphonia, hypokalaemia, muscle cramps.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to the active substances or excipients.International label, same formulation · electronic medicines compendium (eMC)
• Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures; hypersensitivity to any ingredient.International label, same formulation · DailyMed (U.S. NLM)

• Not for acute symptoms (keep a short-acting reliever available); do not start during an exacerbation; do not stop abruptly.International label, same formulation · electronic medicines compendium (eMC)
• Caution in pulmonary tuberculosis or airway infections, severe cardiovascular disorders/arrhythmias, diabetes, and hypokalaemia; paradoxical bronchospasm may occur.International label, same formulation · electronic medicines compendium (eMC)
• Systemic corticosteroid effects may occur at high doses for prolonged periods (adrenal suppression, Cushingoid features, reduced bone mineral density, cataract and glaucoma, growth retardation in children).International label, same formulation · electronic medicines compendium (eMC)

• Beta-blockers (selective and non-selective)May weaken or antagonise the effect of salmeterol; avoid unless compelling reasons.electronic medicines compendium (eMC)
• Ritonavir, cobicistat and other strong CYP3A inhibitorsGreatly increase fluticasone exposure with systemic corticosteroid effects (Cushing syndrome, adrenal suppression); avoid unless benefit outweighs risk.electronic medicines compendium (eMC)
• Ketoconazole (strong CYP3A4 inhibitor)Increases salmeterol exposure, with risk of QTc prolongation and palpitations; avoid.electronic medicines compendium (eMC)

• More than 1000 pregnancy outcomes indicate no malformative or feto/neonatal toxicity; use only if the expected benefit outweighs the risk, with the lowest effective fluticasone dose.International label, same formulation · electronic medicines compendium (eMC)
• Insufficient data on use in pregnant women; animal studies with fluticasone showed corticosteroid-type teratogenicity at maternally toxic subcutaneous doses.International label, same formulation · DailyMed (U.S. NLM)
• Unknown whether salmeterol and fluticasone are excreted in human milk; a risk to the breastfed child cannot be excluded.International label, same formulation · electronic medicines compendium (eMC)

• Fluticasone propionate: Glucocorticoid with potent anti-inflammatory action in the lungs, reducing asthma symptoms and exacerbations.
• Salmeterol (as xinafoate): Selective long-acting beta2 agonist whose long side chain binds the receptor exo-site, giving bronchodilation lasting at least 12 hours.